FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1528463999> ?p ?o ?g. }

• W1528463999 abstract "With the emergence of novel, rationally designed anti-cancer drugs there is also a need for novel endpoints when evaluating these drugs in clinical trials. The combined PET/CT scanner can be a very useful tool in the process of drug development in several ways, which is described in the first chapter of this thesis. PET/CT can be used for patient selection, for measuring the early response to treatment, and for determining the pharmacokinetics and pharmacodynamics of novel anti-cancer drugs. The next chapter describes the novel drug class of the aurora kinase inhibitors. First, the clinical experience with inhibitors of aurora kinase A, B, or both is reviewed. Following this review article, a phase I study with one of these agents, AZD1152, is described. In the subsequent chapters of this thesis, several phase I trials are described with a variety of novel anti-cancer drugs, with various mechanisms of action. These agents include: AZD5438, an inhibitor of cyclin dependent kinases; olaparib (AZD2281), a PARP inhibitor; E7080, an angiogenesis inhibitor; and PF00299804, an inhibitor of HER-1, HER-2, and HER-4 receptor tyrosine kinases. Also, several phase I studies combining targeted anti-cancer drugs with conventional chemotherapy are described. The main goal for all of the described phase I trials in this thesis was to determine the maximum tolerable dose (MTD), dose-limiting toxicities (DLTs), and pharmacokinetics of the investigational drugs. However, increasingly important in these studies are pharmacodynamic endpoints, which can give early indications of the activity of the investigational drugs. Several of the studies in this thesis have successfully implemented pharmacodynamic assays, with the olaparib phase I trial as best example. In this study, target inhibition (reduced activity of the target enzyme poly(ADP-ribose)polymerase) was demonstrated in white blood cells as well as in tumor cells from patients following treatment with olaparib. One of the important conclusions from these results was that there is no need to dose the patients at the MTD since maximal target inhibition is already obtained with lower doses of olaparib. Several of the investigational anti-cancer drugs described in this thesis showed promising activity. Olaparib, for instance, appeared very effective in patients with BRCA deficient breast and ovarian cancer (over half of the patients with BRCA deficient tumors derived clinical benefit from treatment with olaparib). In the phase I trial with E7080, treatment with the angiogenesis inhibitor led to reductions in tumor volume in all patients with melanoma who entered the study. Finally, several partial responses were observed in patients with non-small cell lung cancer following treatment with the pan-HER inhibitor PF00299804.In conclusion, this thesis describes phase I studies with novel anti-cancer agents. Several of the described compounds are now under evaluation in phase II and phase III studies. Future studies with targeted agents should focus more on pharmacodynamic endpoints, and patients for future phase I studies should be included based on their tumor characteristics. PET/CT might be a helpful tool for both these purposes." @default.
• W1528463999 created "2016-06-24" @default.
• W1528463999 creator A5060648247 @default.
• W1528463999 date "2009-10-27" @default.
• W1528463999 modified "2023-09-27" @default.
• W1528463999 title "Safety, pharmacokinetics and pharmacodynamics of targeted anti-cancer drugs" @default.
• W1528463999 cites W141167630 @default.
• W1528463999 cites W1479400057 @default.
• W1528463999 cites W1512626521 @default.
• W1528463999 cites W1523531555 @default.
• W1528463999 cites W1548583460 @default.
• W1528463999 cites W1549846058 @default.
• W1528463999 cites W1550055479 @default.
• W1528463999 cites W1550111394 @default.
• W1528463999 cites W1554530444 @default.
• W1528463999 cites W1562815879 @default.
• W1528463999 cites W1571906792 @default.
• W1528463999 cites W1576680436 @default.
• W1528463999 cites W1594099197 @default.
• W1528463999 cites W1602593566 @default.
• W1528463999 cites W1604537436 @default.
• W1528463999 cites W1629666474 @default.
• W1528463999 cites W1665081245 @default.
• W1528463999 cites W1814543452 @default.
• W1528463999 cites W1839380746 @default.
• W1528463999 cites W1894280592 @default.
• W1528463999 cites W1906314377 @default.
• W1528463999 cites W1907795058 @default.
• W1528463999 cites W1919221066 @default.
• W1528463999 cites W1924227990 @default.
• W1528463999 cites W1925528171 @default.
• W1528463999 cites W1932169383 @default.
• W1528463999 cites W1934942963 @default.
• W1528463999 cites W1937853139 @default.
• W1528463999 cites W1943992522 @default.
• W1528463999 cites W1946819517 @default.
• W1528463999 cites W1957137659 @default.
• W1528463999 cites W1962079151 @default.
• W1528463999 cites W1963701435 @default.
• W1528463999 cites W1964657659 @default.
• W1528463999 cites W1965669510 @default.
• W1528463999 cites W1965734230 @default.
• W1528463999 cites W1966405403 @default.
• W1528463999 cites W1967007810 @default.
• W1528463999 cites W1970356951 @default.
• W1528463999 cites W1970421475 @default.
• W1528463999 cites W1971835091 @default.
• W1528463999 cites W1971837077 @default.
• W1528463999 cites W1971901845 @default.
• W1528463999 cites W1973057373 @default.
• W1528463999 cites W1973268287 @default.
• W1528463999 cites W1973421681 @default.
• W1528463999 cites W1973586213 @default.
• W1528463999 cites W1977409409 @default.
• W1528463999 cites W1977473457 @default.
• W1528463999 cites W1978788134 @default.
• W1528463999 cites W1979706499 @default.
• W1528463999 cites W1980499243 @default.
• W1528463999 cites W1980577287 @default.
• W1528463999 cites W1981073960 @default.
• W1528463999 cites W1981414879 @default.
• W1528463999 cites W1981754363 @default.
• W1528463999 cites W1983863777 @default.
• W1528463999 cites W1983976308 @default.
• W1528463999 cites W1984771830 @default.
• W1528463999 cites W1985826737 @default.
• W1528463999 cites W1986201626 @default.
• W1528463999 cites W1987002881 @default.
• W1528463999 cites W1987496968 @default.
• W1528463999 cites W1987827886 @default.
• W1528463999 cites W1988050012 @default.
• W1528463999 cites W1988464631 @default.
• W1528463999 cites W1988610380 @default.
• W1528463999 cites W1989615266 @default.
• W1528463999 cites W1989779360 @default.
• W1528463999 cites W1990317973 @default.
• W1528463999 cites W1990827442 @default.
• W1528463999 cites W1991054314 @default.
• W1528463999 cites W1991447150 @default.
• W1528463999 cites W1992446787 @default.
• W1528463999 cites W1993561468 @default.
• W1528463999 cites W1993604070 @default.
• W1528463999 cites W1994193851 @default.
• W1528463999 cites W1995563061 @default.
• W1528463999 cites W1995894256 @default.
• W1528463999 cites W1996283150 @default.
• W1528463999 cites W1997361520 @default.
• W1528463999 cites W1998513861 @default.
• W1528463999 cites W1999131612 @default.
• W1528463999 cites W1999178824 @default.
• W1528463999 cites W1999595654 @default.
• W1528463999 cites W1999966467 @default.
• W1528463999 cites W1999966784 @default.
• W1528463999 cites W2000292756 @default.
• W1528463999 cites W2000682857 @default.
• W1528463999 cites W2001334218 @default.
• W1528463999 cites W2001717159 @default.
• W1528463999 cites W2002962154 @default.
• W1528463999 cites W2004631441 @default.
• W1528463999 cites W2006901566 @default.

• next